Russian biosimilar developer Biocad has won a legal battle that will allow it to move forward with its rituximab biosimilar.
Russian biosimilar developer Biocad has won a legal battle that will allow it to move forward with its rituximab biosimilar.
The Pharma Letter reports that Biocad triumphed in a patent dispute over rituximab with Swiss drug developer and maker of the reference rituximab (Rituxan, MabThera), Roche. The Russian government’s Chamber for Patent Disputes announced that Roche—Genentech’s patent covering the use of rituximab in rheumatoid arthritis was invalid. The ruling clears the way for Biocad to produce and commercialize a biosimilar of the anti–tumor necrosis factor agent that is used in the treatment of both cancer and rheumatologic diseases.
In June, Biocad gained authorization to market the biosimilar rituximab as Usmal in Bolivia and Honduras, and has already begun selling the drug in 7 other markets, including Kazakhstan, Vietnam, and Sri Lanka.
Biocad also announced its intentions to enter the European marketplace with both its innovator and biosimilar products, and said that it expects to receive marketing authorization from the European Medicines Association beginning in 2021. According to Biocad, the company is ready to provide dossiers of its medicines that align with the International Council for Harmonization Common Technical Document format. In May, Biocad took its first steps toward European market entry when it established a new Eurozone presence in Turku, Finland. Biocad plans to invest €25 million (approximately $28 million) in Finland’s Turku region over the next 7 years as it continues to develop products for the European market.
Despite its legal gains in Russia and its eye on global expansion, Biocad still faces hurdles to entering the United States market; in 2016, Biocad filed suit in a New York district court alleging that competitor Roche and other drug makers were engaged in an anticompetitive scheme that blocked Biocad from entering the US oncology drug marketplace. Biocad alleged that its competitors were increasing the prices of their drugs in the United States while selling the same products at deep discounts in Russia.
The judge dismissed the case, saying that US antitrust laws do not extend to conduct in Russia, and the effect of the activities in Russia on the United States market were too attenuated for the court to have jurisdiction over the claims.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.